Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06335108
Other study ID # SenoEx_TLA_Maligne
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 5, 2022
Est. completion date December 1, 2024

Study information

Verified date March 2024
Source University Hospital Tuebingen
Contact Bettina Böer, Dr.
Phone +49 7071 29 82211
Email Bettina.Boeer@med.uni-tuebingen.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The present study aims to investigate the impact of Tumescent Local Anesthesia (TLA) on pain perception following surgeries typical for breast cancer. Previous research has already confirmed the feasibility of conducting operations in TLA for benign breast conditions. In contrast to general anesthesia, Tumescent Local Anesthesia involves local anesthesia of the surgical site, allowing patients to remain awake during the procedure and eliminating the risks associated with general anesthesia. Additionally, if needed, sedatives or further anesthesia can be administered through the vein. Building upon the successful applications of TLA in benign breast surgeries, this follow-up study at the Department of Women's Health focuses on enhancing surgical techniques, pain management, and postoperative care for breast cancer-related procedures. Simultaneously, our goal is to gather scientific data regarding the application of this technique. This research contributes to the continuous advancement of medical practices in the field of breast surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Written informed consent - Histologically confirmed breast carcinoma or pure ductal carcinoma in situ - Planned operation: - Segmental resection/ breast-conserving surgery - Segmental resection/ breast-conserving surgery with SNB - Ablatio - Ablatio with SNB/ axilla exploration Exclusion Criteria: - Expected lack of patient compliance or inability of the patient to understand the purpose of the study - Lack of patient consent - Pregnancy - Complete axillary dissection - Tumour-adapted reduction surgery, implant reconstructions - Surgeries where technical difficulties are expected under any anaesthesia (e.g. ASA IV, BMI > 40) - Bilateral breast operations - Men Exclusion Criteria for surgery in TLA: - Injection phobia - Psychoses/ previous psychological illnesses - Advanced dementia - Language barrier

Study Design


Intervention

Procedure:
General Anaesthesia
Breast surgery is carried out under general anesthesia.
Local tumescent anaesthesia
Breast surgery is carried out under local tumescent anesthesia.

Locations

Country Name City State
Germany University Women's Hospital Tübingen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative Pain The primary endpoint is the recording of postoperative pain. Pain will be measured on 1.-3. postoperative day using the Visual Analogue Scale (VAS). The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
Additionally, the postoperative pain will be assessed using the VAS at the post-operative follow-up consultation, which usually takes place 2-5 weeks after surgery.
5 weeks
Secondary HRQoL/ Quality of life The outcome measure for Health-Related Quality of Life (HRQoL) in this study utilizes the Breast-Q questionnaire specific to breast cancer (BCT/Mastectomy). Preoperative assessments are conducted during the recruitment phase following participants' consent, providing baseline HRQoL data. Postoperative evaluations occur 2-5 weeks after the surgery during follow-up discussions, capturing changes in HRQoL in the immediate aftermath of the mastectomy and informing the study about the impact of the surgical intervention on participants' quality of life. 5 weeks
Secondary Postoperative pain medication requirements The outcome measure for postoperative pain medication requirements includes the assessment of administered pain medications, encompassing anti-inflammatory drugs, opioids, and non-opioid analgesics.
Patient's medical records will be examined to identify the pain medications administered postoperatively. The administered pain medications will then be categorized into anti-inflammatory drugs, opioids, and non-opioid analgesics. The total dosage of each type of pain medication administered will be calculated until hospital dischanrge. To evaluate the effectiveness of the administered pain medications in managing postoperative pain, pain assessment tool (Visual Analog Scale) will be used to measure pain intensity (2-3x daily for exercise and rest). On the first postoperative day, patients also receive the standardized QUIPS pain questionnaire consisting of 16 questions pain assesement after operation.
5 weeks
Secondary Complications Complications in the study will be recorded during the hospital stay and post-operative follow-up, using the Clavien- Dindo classification system to categorize and assess their severity, contributing vital insights into the safety and efficacy of the surgical intervention. 5 weeks
Secondary Length of hospital stay The "length of hospital stay" refers to the time elapsed from a patient's admission to their discharge. 1 day until 2 weeks
Secondary Duration of surgery In the current clinical study, the duration of surgery, measured as the time from incision to wound closure, will be meticulously recorded using precise timekeeping instruments. This involves capturing the elapsed time from the moment the surgical incision is made to the point when the wound is closed. 1 until 5 hours
Secondary Drainage delivery rate The drainage delivery rate will be assessed by measuring the volume of fluid collected by the drainage system until the point of discharge. This involves tracking the total volume in milliliters (ml) accumulated over the entire duration of drainage until the patient is discharged. Surgery until discharge (1 day until 2 weeks )
Secondary Follow-up surgery for R1 situation An additional outcome criterion is whether there is a R1 situation with subsequent surgery, answered yes/no. 5 hours
Secondary Preoperative fear of surgery and anaesthesia The secondary outcome criterion, "preoperative fear of surgery and anesthesia," will be assessed using the APAIS (Amsterdam Preoperative Anxiety and Information Scale) questionnaire and a Visual Analog Scale (VAS) ranging from 0 to 10. The APAIS questionnaire consists of multiple items measuring anxiety and information desire related to surgery and anesthesia, with higher scores indicating greater preoperative fear. The Visual Analog Scale, ranging from 0 (no fear) to 10 (extreme fear), allows participants to subjectively rate their apprehension, providing a numerical representation of the intensity of preoperative fear. 30 Minutes
Secondary Costs The costs of breast surgery conducted under general anesthesia versus local anesthesia serve as a crucial outcome criterion in the clinical study. This assessment involves comparing the overall expenses associated with each anesthesia method, including anesthesia administration, recovery, and potential complications, to determine the economic implications and cost-effectiveness of the two approaches in the context of breast surgery. 5 weeks
Secondary Satisfaction of the surgeon with the course of the operation The satisfaction of the surgeon with the course of the operation will be measured on a scale of 0 to 10, where 0 represents not satisfied at all and 10 signifies extreme satisfaction. 5 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04996316 - MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals
Enrolling by invitation NCT05558917 - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery N/A
Completed NCT05526872 - A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening N/A
Not yet recruiting NCT05178498 - Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Recruiting NCT05544123 - The Treatment Situation of Chinese County Population With Breast Cancer
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01422408 - Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy Phase 2
Terminated NCT02810873 - Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer N/A
Terminated NCT00770354 - Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer Phase 2
Withdrawn NCT03185871 - Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses Phase 2
Completed NCT02983279 - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT05406232 - Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Recruiting NCT03408353 - Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
Completed NCT01641068 - Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms N/A
Withdrawn NCT04190433 - Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial Phase 2
Recruiting NCT04799535 - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Terminated NCT02923037 - Hatha Yoga in Breast Cancer Survivors N/A